Why the study?
Does aspirin or other antiplatelet treatment prevent venous thromboembolism in patients at high risk?
Does aspirin or other antiplatelet treatment prevent venous thromboembolism in patients at high risk?
Answers are grounded in this paper and cite their sources.
This paper challenges the recommendation from the Antiplatelet Trialists' Collaboration to use antiplatelet therapy for venous thromboprophylaxis.
A recent meta-analysis from the Antiplatelet Trialists' Collaboration recommended that antilatelet treatment either alone or, for greater effect, in addition to other proved forms of thromboprophylaxis should be considered for patients at high risk of thromboembolism. This paper argues that the current evidence does not justify the adoption of aspirin or other antiplatelet treatment for venous thromboprophylaxis, especially when more effective alternatives exist. Furthermore, several issues relating to this latest meta-analysis need to be debated.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: